Clinical Trial

Stellate Ganglion Blockade for Refractory Chronic Migraine

Study acronym: SGB-RCM
Completed
View on ClinicalTrials.gov →
Summary
Stellate Ganglion Block (SGB) is an interventional anesthetic technique used to treat pain conditions affecting the head, face, neck, and upper extremities by temporarily blocking sympathetic nerve output. Ultrasound guidance improves anatomical visualization and enhances procedural safety. Emerging evidence suggests that repeated ultrasound-guided SGB may reduce headache intensity and frequency in migraine patients and may improve migraine-related disability. However, limited data exist regarding its role in highly treatment-resistant chronic migraine, particularly in patients who have not responded adequately to preventive pharmacological therapies and peripheral nerve block interventions. The primary objective of this study is to evaluate the clinical efficacy of ultrasound-guided SGB in patients with treatment-resistant chronic migraine. Secondary objectives include assessing changes in migraine-related disability and monitoring potential adverse events.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-17.
Status change: Active, Not Recruiting → Completed 2026-02-25
Trial Details
NCT Number NCT06891118
Lead Sponsor Ankara City Hospital Bilkent
Conditions Headache, Migraine, Chronic Migraine Headache
Enrollment 42 participants
Start Date 2024-03-06
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27